Trial Profile
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 29 Jan 2024 Planned End Date changed from 23 Dec 2023 to 23 Mar 2024.
- 29 Jan 2024 Planned primary completion date changed from 23 Dec 2023 to 23 Mar 2024.
- 12 Sep 2023 Planned End Date changed from 23 Aug 2023 to 23 Dec 2023.